CommercialAdministrativeLow impact
08.01.22d, Alemtuzumab (Lemtrada®)
Independence Blue Cross·Neurology, Oncology, Hematology·Pharmacy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
A reissue of the Alemtuzumab (Lemtrada®) pharmacy policy has been posted for commercial plans. This appears to be a routine policy reissuance with no indication of substantive changes to coverage or billing requirements.
Action Required
By April 2, 2025: Billing team should review the updated Alemtuzumab (Lemtrada®) policy at the provided URL to identify any changes to prior authorization requirements or coverage criteria for this specialty multiple sclerosis medication. No immediate action appears required as this is marked as a reissue.